Sanofi Egypt
Sanofi Egypt is the Cairo-based Egyptian subsidiary of Paris-headquartered pharmaceutical group Sanofi S.A., distributing innovative medicines across multiple therapy areas to Egyptian hospitals, pharmacies, and patients, and engaging with Egypt's Drug Authority on regulatory and investment matters.
- Company typePublic
- Founded1973
- HeadquartersCairo, Egypt
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Sanofi Egypt does
Sanofi Egypt is the Cairo-based Egyptian subsidiary of Sanofi S.A., the Paris-headquartered multinational pharmaceutical group publicly listed on Euronext Paris (ticker SAN) with ADRs on NASDAQ. Sanofi Egypt operates within Sanofi's global pharmaceutical manufacturing and commercialization network, distributing innovative medicines across multiple therapy areas — respiratory diseases, diabetes, vaccines, dermatology, cardiovascular, oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Pompe), transplant medicine, eosinophilic esophagitis, and thyroid disorders — to Egyptian healthcare providers including hospitals, pharmacies, and patients. The subsidiary is staffed by 10,000+ employees at the global parent level with a local managing director (Adrien Delamare-Deboutteville), and participates actively in regulatory dialogue with Egypt's Drug Authority (EDA) on market access and drug system strengthening.
The company monetizes through pharmaceutical product sales distributed via established healthcare supply chains in Egypt. Pricing models are not publicly disclosed. Distribution reaches Egyptian prescribers and dispensers through standard pharma channels, with parallel support from global Sanofi digital platforms including mein.sanofi.de (patient and healthcare professional portal), the Sanofi Product Database, Medical Information services, and the parent group's Health x Tomorrow digitalization initiative. The Egypt subsidiary is governed by EDA regulatory frameworks and benefits from Sanofi's flexible, internationally-aligned regulatory engagement strategy affirmed in a 2025-11-18 meeting with EDA Chairman Dr. Ali El-Ghamrawy.
Sanofi Egypt sits within a global parent (Sanofi S.A.) that generated approximately €50.3 billion in total FY2023 revenue, with R&D infrastructure spanning biologics, technology platforms, and clinical studies. Sub-brands including Sandoz (generics) and Genzyme (rare disease biotechnology) are part of the parent's portfolio and inform the therapeutic range potentially accessible to the Egyptian market. The Egypt entity itself does not have disclosed standalone revenue, headcount, or Egypt-specific R&D investments in the available data, positioning it as a commercial/regulatory operating subsidiary rather than a standalone R&D hub.
Sanofi Egypt firmographics
Firmographics- Name
- Sanofi Egypt
- Legal name
- Sanofi S.A.
- Website
- https://sanofi-aventis.de
- Company type
- Public
- Founded year
- 1973
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Sanofi Egypt is the Cairo-based Egyptian subsidiary of Paris-headquartered pharmaceutical group Sanofi S.A., distributing innovative medicines across multiple therapy areas to Egyptian hospitals, pharmacies, and patients, and engaging with Egypt's Drug Authority on regulatory and investment matters.
- Ownership category
- akta.pro rank
Sanofi Egypt industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI)
- akta.pro secondary industry
- Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)
Keywords
Where Sanofi Egypt is headquartered
LocationHeadquarters
- HQ city
- Cairo
- HQ country
- Egypt
- HQ region
- Africa
Offices1 record
Markets served
Sanofi Egypt business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales
Sanofi Egypt product offering
Product offeringCore offering
Sanofi Egypt is a pharmaceutical manufacturing subsidiary that develops, manufactures, and distributes innovative medicines across multiple therapy areas including respiratory diseases, diabetes, vaccines, dermatology, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company supports its pharmaceutical portfolio with digital health portals and medical information services for patients and healthcare professionals, and engages with Egypt's Drug Authority to accelerate availability of innovative medicines in the Egyptian market.
Product overview
Sanofi is a research-based biopharma company offering a broad portfolio of innovative therapies across multiple therapy areas including respiratory diseases (asthma, nasal polyps), diabetes, vaccines, dermatology (atopic dermatitis), cardiovascular diseases (cholesterol management), oncology, multiple sclerosis, rheumatology, rare diseases (Gaucher, Pompe), transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company provides patient and healthcare professional-facing digital portals (mein.sanofi.de, product database, medical information services) alongside its therapeutic products. The product portfolio spans both pharmaceutical medications and digital health solutions under the Health x Tomorrow digitalization initiative. Research and development capabilities include biologics and technology platforms supporting drug discovery and manufacturing.
Differentiator
Problem solved
Functional benefit
Brands
- Sandoz: Generic pharmaceuticals division of Sanofi
- Genzyme
Products and services
- Respiratory Disease Treatments (Atemwegserkrankungen) Treatment solutions for respiratory conditions including asthma and nasal polyps, offered as part of Sanofi's pharmaceutical portfolio in Egypt.
- Diabetes Treatments Diabetes treatment and management pharmaceutical solutions for patients in Egypt.
- Vaccines (Impfstoffe) Vaccine products and immunization solutions distributed through the Egyptian healthcare supply chain.
- Dermatology Treatments (Hauterkrankungen) Dermatological pharmaceutical treatments including atopic dermatitis.
- Cardiovascular Disease Treatments (Herz-Kreislauf-Erkrankungen) Cardiovascular disease pharmaceutical treatments including cholesterol management.
- Oncology Treatments (Krebserkrankungen) Oncology pharmaceutical treatment solutions for cancer patients.
- Multiple Sclerosis Treatments (Multiple Sklerose) Neurological disorder pharmaceutical treatments for multiple sclerosis patients.
- Rheumatology Treatments (Rheumatologie) Rheumatological disease pharmaceutical treatments.
- Rare Disease Treatments (Seltene Erkrankungen) Orphan disease pharmaceutical treatments including Gaucher disease and Pompe disease.
- Transplant Medicine Treatments (Transplantationsmedizin) Pharmaceutical treatments for transplant rejection prevention.
- Eosinophilic Esophagitis Treatments (Eosinophile Ösophagitis) Specialized pharmaceutical treatment for eosinophilic esophagitis.
- Thyroid Disease Treatments (Schilddrüsenerkrankungen) Thyroid disorder pharmaceutical treatments including thyroid cancer.
Companies that use Sanofi Egypt
Customer profileSegments1 record
Ideal customer profiles1 record
Sanofi Egypt technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Sanofi Egypt partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Egypt's Drug Authority (EDA)coreEDA Chairman Dr. Ali El-Ghamrawy met with Sanofi representatives to discuss mechanisms for strengthening Egypt's drug system and supporting investment. The authority affirmed commitment to flexible regulatory policies aligned with international practices to ensure accelerated availability of innovative medicines and market competitiveness. Sanofi expressed appreciation for EDA's participatory approach, stating cooperation opens prospects for further investment and treatment access in Egypt.
- AstraZenecaminorPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
- SandozminorPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
- PfizerminorPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
- RocheminorPharmaceutical company participating alongside Sanofi in discussions with Egypt's Drug Authority regarding market stability and investment opportunities.
Recent moves5 records
Expansion highlights5 records
Sanofi Egypt competitors and assessment
Company assessmentDirect peers
- AstraZeneca: Global multinational pharmaceutical company with a presence in Egypt across oncology, cardiovascular, respiratory, and rare disease therapy areas. Co-participant with Sanofi in EDA regulatory dialogue in 2025, confirming direct market overlap and comparable business model.
- Pfizer: One of the world's largest pharmaceutical manufacturers with established operations in Egypt spanning vaccines, oncology, and primary care. Co-participant with Sanofi in EDA regulatory discussions, indicating directly comparable market footprint and portfolio breadth.
- Eli Lilly: US multinational pharmaceutical company with presence in Egypt across diabetes, oncology, immunology, and neuroscience. Direct competitor to Sanofi especially in diabetes, an area where Sanofi has a strong therapy-area focus.
- GlaxoSmithKline (GSK): British multinational pharmaceutical company with strong presence in Egypt across vaccines, respiratory, and HIV therapy areas. Directly comparable multinational subsidiary model with overlapping therapy-area portfolio.
- Roche: Multinational pharmaceutical and diagnostics leader with significant presence in Egypt, particularly in oncology and specialty care. Co-participant with Sanofi in EDA regulatory meetings, indicating directly comparable multinational subsidiary structure in Egypt.
- Merck & Co. (MSD): US-based multinational pharmaceutical company with established operations in Egypt across oncology, vaccines, and animal health. Comparable multinational subsidiary structure and therapy-area portfolio breadth.
- Novartis: Global Swiss pharmaceutical company operating across innovative medicines and generics (Sandoz), with established Egypt presence. Comparable multinational subsidiary structure with similar branded therapy-area portfolio overlap to Sanofi.
Broad incumbents
- Johnson & Johnson: Diversified healthcare conglomerate with pharmaceutical operations across immunology, oncology, and neuroscience, with established Egypt presence. Broader portfolio beyond pharma but directly comparable pharmaceutical subsidiary operations.
- Abbott: Diversified healthcare company with pharmaceutical, diagnostics, nutritionals, and medical devices divisions, with established Egypt presence. Comparable multinational subsidiary structure with broader healthcare portfolio than pure-play pharma.
Regional players
- Eva Pharma: Leading Egyptian pharmaceutical manufacturer with strong local market presence across branded generics and innovative medicines. Direct competitor to multinational subsidiaries like Sanofi Egypt in the domestic Egyptian pharmaceutical market.
Market position
Strengths4 records
Weaknesses3 records
Competitive moat5 records
Key risks4 records
Key highlights5 records
Customer concentration
Sanofi Egypt social profiles
Digital presenceSanofi Egypt financial estimates
Financial estimateRevenue estimate
Valuation estimate
Sanofi Egypt leadership team
Management profileNumber of profiles
Profiles1 record
Sanofi Egypt subsidiaries and ownership
Company hierarchySubsidiaries2 records
Sanofi Egypt funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Sanofi Egypt M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Sanofi Egypt
What does Sanofi Egypt do?
Sanofi Egypt is a pharmaceutical manufacturing subsidiary that develops, manufactures, and distributes innovative medicines across multiple therapy areas including respiratory diseases, diabetes, vaccines, dermatology, cardiovascular diseases, oncology, multiple sclerosis, rheumatology, rare diseases, transplant medicine, eosinophilic esophagitis, and thyroid disorders. The company supports its pharmaceutical portfolio with digital health portals and medical information services for patients and healthcare professionals, and engages with Egypt's Drug Authority to accelerate availability of innovative medicines in the Egyptian market.
Is Sanofi Egypt a public or private company?
Sanofi Egypt is a public company. It is classified as public and is currently operating.
When was Sanofi Egypt founded?
Sanofi Egypt was founded in 1973. It employs 5,001 to 10,000 people.
Where is Sanofi Egypt based?
Sanofi Egypt is headquartered in Cairo, Egypt, in the Africa region.
Who are Sanofi Egypt's main competitors?
Direct peers on record are AstraZeneca, Pfizer, Eli Lilly, GlaxoSmithKline (GSK), Roche, Merck & Co. (MSD) and Novartis. Broad incumbents are Johnson & Johnson and Abbott. Eva Pharma is listed as a regional player.
Does Sanofi Egypt have an API?
No public API is recorded for Sanofi Egypt.
What industry is Sanofi Egypt in?
Sanofi Egypt's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAI, Gastroenterology & Hepatology Pharmaceuticals, with a secondary code of HLAIAJAF, Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor). Its NAICS code is 325412 and its SIC code is 2834.